Laboratory-confirmed Clostridioides difficile infection after potassium-competitive acid blocker versus proton pump inhibitor initiation in a new-user cohort
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Comparative gastrointestinal infection safety of potassium-competitive acid blockers (PCABs) and proton pump inhibitors (PPIs) remains uncertain. In this study, we compared laboratory-confirmed Clostridioides difficile infection (CDI) after initiation of these drug classes in a hospital cohort. Methods In this retrospective active-comparator new-user cohort, prescription and stool-test records from a Korean hospital clinical data warehouse were linked. Adults initiated PCABs or PPIs between January 2020 and June 2025, after a 1-year washout for both drug classes and without CDI during the prior 5 years. PCAB and PPI initiators were matched 1:4 using propensity scores. Cox models estimated hazard ratios for incident laboratory-confirmed CDI. Results The matched cohort included 13,714 PCAB initiators and 54,856 PPI initiators, with 30 and 267 CDI events, respectively. Incidence rates were 5.69 and 7.15 per 1,000 person-years; mean observed follow-up was 140.5 and 248.8 days, respectively. PCAB initiation was associated with a lower observed CDI incidence (hazard ratio, 0.57; 95% confidence interval, 0.39–0.84). Nested secondary outcomes showed associations in the same direction. Conclusions In this single-center observational cohort, PCAB initiation was associated with a lower observed incidence of laboratory-confirmed CDI than PPI initiation. These findings add comparative gastrointestinal safety evidence for newer acid-suppressive therapies and support confirmation in multicenter cohorts. The observational association does not establish causal protection or individual-agent superiority.
Source: Research Square
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7234062101
